有效白蛋白在慢性肝病中的作用

doi:10.16352/j.issn.1001-6325.2024.12.1707

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (12): 1707-1711.doi: 10.16352/j.issn.1001-6325.2024.12.1707

有效白蛋白在慢性肝病中的作用

林钧¹, 李泽鹏^2*, 余君莹¹

1.广西中医药大学,广西南宁 530000;
2.柳州市中医医院感染性疾病科,广西柳州 545000

收稿日期:2024-03-04 修回日期:2024-06-04 出版日期:2024-12-05 发布日期:2024-11-26
通讯作者: ^*329562397@qq.com
基金资助:
国家自然科学基金(82160882);广西省自然科学基金青年基金(2020GXNSFBA297133);广西中医药适宜技术开发与推广项目(GZSY2024077)

The role of effective albumin in chronic liver disease

LIN Jun¹, LI Zepeng^2*, YU Junying¹

1. Guangxi University of Traditional Chinese Medicine, Nanning 530000;
2. Department of Infectious Diseases, Liuzhou Hospital of Traditional Chinese Medicine, Liuzhou 545000, China

Received:2024-03-04 Revised:2024-06-04 Online:2024-12-05 Published:2024-11-26
Contact: ^*329562397@qq.com

摘要/Abstract

摘要： 有效白蛋白是指结构和功能保持完好的血清白蛋白,在慢性肝病进程中,部分血清白蛋白经过氧化、糖基化等不同的翻译后修饰丧失其功能完整性。有效白蛋白的水平在肝硬化失代偿期患者中较低,与患者的生存率密切相关,强调了其在反映肝功能实际状况方面比总血清白蛋白更为敏锐。此外,有效白蛋白不仅可作为预测指标,还能改善白蛋白制剂和开发新的治疗方法,在治疗慢性肝病中发挥关键作用。

关键词: 有效白蛋白, 肝硬化, 肝衰竭, 肝癌

Abstract: Effective albumin refers to serum albumin with intact structure and function. In the course of chronic liver disease, some serum albumin loses its functional integrity through different post-translational modifications such as oxidation and glycosylation. Level of effective albumin is lower in patients with decompensated cirrhosis and is significantly correlated with patient survival, underscoring that they are more sensitive than total serum albumin in reflecting the actual state of liver function. In addition, effective albumin not only serves as a predictor, but also plays a key role in the treatment of chronic liver disease by improving albumin preparations and developing new therapeutics.

Key words: effective albumin, liver cirrhosis, liver failure, liver cancer

中图分类号:

R575.5

林钧, 李泽鹏, 余君莹. 有效白蛋白在慢性肝病中的作用[J]. 基础医学与临床, 2024, 44(12): 1707-1711.

LIN Jun, LI Zepeng, YU Junying. The role of effective albumin in chronic liver disease[J]. Basic & Clinical Medicine, 2024, 44(12): 1707-1711.

参考文献

[1]Griffin C, Agbim U, Ramani A, et al. Underestimation of cirrhosis-related mortality in the medicare eligible population, 1999-2018[J]. Clin Gastroenterol Hepatol, 2023, 21: 223-225.e3. doi: 10.1016/j.cgh.2021.10.036.
[2]Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality[J]. Hepatol Baltim Md, 2009, 50: 555-564. doi: 10.1002/hep.22913.
[3]Wu N, Liu T, Tian M, et al. Albumin, an interesting and functionally diverse protein, varies from “native” to “effective”[J]. Mol Med Rep, 2024, 29: 24. doi: 10.3892/mmr.2023.13147.
[4]Liu B, Yasukawa K, Koid SS, et al. A rapid method for measuring serum oxidized albumin in a rat model of proteinuria and hypertension[J]. Sci Rep, 2019, 9: 8620. doi: 10.1038/s41598-019-45134-x.
[5]Jalan R, Bernardi M. Effective albumin concentration and cirrhosis mortality: from concept to reality[J]. J Hepatol, 2013, 59: 918-920. doi: 10.1016/j.jhep.2013.08.001.
[6]Wu D, Gucwa M, Czub MP, et al. Structural and biochemical characterisation of Co2+-binding sites on serum albumins and their interplay with fatty acids[J]. Chem Sci, 2023, 14: 6244-6258. doi: 10.1039/d3sc01723k.
[7]Paar M, Fengler VH, Reibnegger G, et al. Determina-tion of binding characteristics as a measure for effective albumin using different methods[J]. Biochim Biophys Acta Gen Subj, 2023, 1867: 130427. doi: 10.1016/j.bbagen.2023.130427.
[8]Klinkmann G, Waterstradt K, Klammt S, et al. Exploring albumin functionality assays: a pilot study on sepsis evaluation in intensive care medicine[J]. Int J Mol Sci, 2023, 24: 12551. doi: 10.3390/ijms241612551.
[9]孙立杰, 郝丹丹. 诱导肝星状细胞铁死亡治疗肝纤维化的研究进展[J]. 基础医学与临床, 2024, 44: 108-113.
[10]Baldassarre M, Naldi M, Zaccherini G, et al. Determination of effective albumin in patients with decompensated cirrhosis: clinical and prognostic implications[J]. Hepatol Baltim Md, 2021, 74: 2058-2073. doi: 10.1007/s12325-023-02430-3.
[11]Zheng X, Bai Z, Wang T, et al. Human albumin infusion for the management of liver cirrhosis and its complica-tions: an overview of major findings from meta-analyses[J]. Adv Ther, 2023, 40: 1494-1529. doi: 10.1007/s12325-023-02430-3.
[12]Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis: an open-label randomised trial[J]. Lancet, 2018, 391: 2417-2429. doi: 10.1016/S0140-6736(18)30840-7.
[13]Bai Z, Wang L, Wang R, et al. Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials[J]. Hepatol Int, 2022, 16: 1468-1483. doi: 10.1007/s12072-022-10374-z.
[14]Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. a randomized placebo-controlled trial[J]. J Hepatol, 2018, 69: 1250-1259. doi: 10.1016/j.jhep.2018.08.006.
[15]Xu T, Liu W, Huang R. Can albumin reduce the mortality of patients with cirrhosis and ascites? a meta-analysis of randomized controlled trials[J]. Eur J Gastroenterol Hepatol, 2023, 35: 80-88. doi: 10.1097/MEG.0000000000002447.
[16]Plantier JL, Duretz V, Devos V, et al. Comparison of antioxidant properties of different therapeutic albumin preparations[J]. Biol J Int Assoc Biol Stand, 2016, 44: 226-233. doi: 10.1016/j.biologicals.2016.04.002.
[17]Miyamura S, Imafuku T, Anraku M, et al. Comparison of posttranslational modification and the functional impair-ment of human serum albumin in commercial preparations[J]. J Pharm Sci, 2016, 105: 1043-1049. doi: 10.1016/j.xphs.2015.12.015.
[18]Bañares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the relief trial[J]. Hepatol Baltim Md, 2013, 57: 1153-1162. doi: 10.1002/hep.26185.
[19]Kreymann B, Seige M, Schweigart U, et al. Albumin dialysis: effective removal of copper in a patient with fulminant wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins[J]. J Hepatol, 1999, 31: 1080-1085. doi: 10.1016/s0168-8278(99)80322-5.
[20]Chawla LS, Georgescu F, Abell B, et al. Modification of continuous venovenous hemodiafiltration with single-pass albumin dialysate allows for removal of serum bilirubin[J]. Am J Kidney Dis, 2005, 45: e51-e56. doi: 10.1053/j.ajkd.2004.11.023.
[21]Lei Q, Zhang Y, Ke C, et al. Value of the albumin-bilirubin score in the evaluation of hepatitis B virus-related acute-on-chronic liver failure, liver cirrhosis, and hepatocellular carcinoma[J]. Exp Ther Med, 2018, 15: 3074-3079. doi: 10.3892/etm.2018.5748.
[22]Sheng Y, Zeng Y, Luo W, et al. Predictive value of the prothrombin time-international normalized ratio to albumin ratio in the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Int J Gen Med, 2023, 16: 4565-4572. doi: 10.2147/IJGM.S434572.
[23]Lin H, Fan Y, Wieser A, et al. Albumin might attenuate bacteria-induced damage on kupffer cells for patients with chronic liver disease[J]. Cells, 2021, 10: 2298. doi: 10.3390/cells10092298.
[24]Duran-Güell M, Garrabou G, Flores-Costa R, et al. Essential role for albumin in preserving liver cells from TNFα-induced mitochondrial injury[J]. FASEB J, 2023, 37: e22817. doi: 10.1096/fj.202201526R.

有效白蛋白在慢性肝病中的作用

The role of effective albumin in chronic liver disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李顺乐, 李蓉, 田亚亚, 冉小丽, 赵延培, 徐蒙. 血清KLF5和actinin-4水平与肝细胞肝癌肝动脉化疗栓塞术治疗预后的关系[J]. 基础医学与临床, 2024, 44(9): 1284-1289.
[2]	安琪, 齐光照, 韩超. 桃叶珊瑚苷抑制人肝癌细胞系HepG2增殖[J]. 基础医学与临床, 2024, 44(3): 333-338.
[3]	郭鑫, 冀梦蝶, 王琦, 李雪媛, 陈阳. 鉴定顺铂对人肝癌细胞系转录物组的影响[J]. 基础医学与临床, 2024, 44(3): 352-360.
[4]	卢慧莹, 王建国. 下调去甲基化酶FTO抑制人肝癌细胞系HepG2增殖[J]. 基础医学与临床, 2024, 44(2): 185-191.
[5]	齐泽强, 郭庭煜, 吴治念, 王亚东. 骨髓间充质干细胞治疗肝衰竭的作用机制[J]. 基础医学与临床, 2024, 44(11): 1608-1612.
[6]	杨雅倩, 潘艳芳, 屈梦扬, 方艳, 应小平, 张玫倩, 魏静. 外泌体在肝癌前病变发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(9): 1453-1456.
[7]	邢雪梅, 杨建睿, 李治君, 陈雅娟, 姚凤霞, 刘征. 免疫球蛋白用于原发性胆汁性胆管炎、戊型肝炎、肝硬化的鉴别诊断[J]. 基础医学与临床, 2023, 43(8): 1271-1274.
[8]	孙全鹏, 樊超, 展德玺, 范怡明, 孙伟峰. 罗哌卡因抑制人肝癌细胞系Hep3B增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(3): 448-453.
[9]	黄容, 张键, 车旭. SLC4A10表达水平对肝癌患者预后的影响[J]. 基础医学与临床, 2022, 42(3): 461-466.
[10]	米月, 蒋琦炜, 沈雁婕, 张德宇, 叶棋浓. 激活蛋白2家族基因真核表达载体的构建及其功能鉴定[J]. 基础医学与临床, 2022, 42(12): 1829-1834.
[11]	唐加峰, 何雪莲, 夏菁, 熊伟, 李小山. 熊果酸联合HDAC2抑制剂抑制人肝癌细胞系HepG2的增殖[J]. 基础医学与临床, 2021, 41(8): 1144-1150.
[12]	李长安, 刘春秀, 谢晓娟, 孙爱平. 下调Notch1基因促进人肝癌细胞系HepG2自噬[J]. 基础医学与临床, 2021, 41(4): 508-513.
[13]	吴娜, 王东, 李京敏, 白咸勇. 羟基红花黄色素A抑制人肝癌细胞系Huh7发生上皮-间质转化[J]. 基础医学与临床, 2021, 41(10): 1423-1427.
[14]	唐卫平, 李翀, 陈国栋, 赵磊. 大鼠脾切除对移植脂肪间充质干细胞的肝脏归巢效率及肝硬化的影响[J]. 基础医学与临床, 2021, 41(10): 1428-1433.
[15]	田小星, 秦溧嫔, 李茜. 长链非编码RNA TINCR通过miR-7调控肝癌细胞系Huh7侵袭和迁移[J]. 基础医学与临床, 2020, 40(8): 1041-1046.